Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;10(16):877.
doi: 10.21037/atm-22-3592.

Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer: a retrospective single-armed cohort study in China

Yu Qian  1 , Ying Peng  2 , Hao Zhou  2 , Lili Zhang  2 , Yuan Yuan  2
Affiliations

Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer: a retrospective single-armed cohort study in China

Yu Qian et al. Ann Transl Med. 2022 Aug.

Abstract

Background: There are currently few studies on the efficacy and safety of the dual human epidermal growth factor receptor 2 (HER2)-targeted combination of trastuzumab and pertuzumab in second-line or subsequent therapy of metastatic breast cancer (MBC). This study retrospectively demonstrated the clinical efficacy and side effects of trastuzumab plus pertuzumab in combination with chemotherapy in HER2-positive MBC.

Methods: Patients with HER2-positive MBC and treated with trastuzumab plus pertuzumab combined with chemotherapy at our hospital between August 2013 and October 2021 were included. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were disease control rate (DCR), objective response rate (ORR), clinical benefit rate (CBR), and side effects. PFS was calculated using the Kaplan-Meier method and side effects were assessed according to Common Terminology Criteria for Adverse Events 5.0.

Results: A total of 55 women were included and the median PFS for trastuzumab plus pertuzumab combined with chemotherapy was 10 months. For the different treatment lines, the median PFS was 19, 8, and 5 months in first, second, and third and beyond, respectively. The DCR, ORR, and CBR were 81.8%, 47.3%, and 56.4%, respectively. The median PFS of patients with primary trastuzumab resistance was significantly shorter than trastuzumab-sensitive patients (5 vs. 12 months, P=0.011). The most common adverse reactions were neutropenia (40.0%), leukopenia (34.5%), thrombocytopenia (32.7%), and diarrhea (29.1%). The most common grade 3-4 adverse reactions were leukopenia (12.7%), thrombocytopenia (9.1%), and diarrhea (9.1%).

Conclusions: For patients with HER2-positive MBC, treatment with trastuzumab plus pertuzumab combined with chemotherapy appeared efficacious and safe.

Keywords: Trastuzumab; human epidermal growth factor receptor 2 positive (HER2-positive); metastatic breast cancer (MBC); pertuzumab; side effects.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-3592/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
PFS curves of 55 patients with metastatic HER2-positive breast cancer treated with trastuzumab plus pertuzumab in combination with chemotherapy. PFS, progression-free survival; HER2, human epidermal growth factor receptor 2.
Figure 2
Figure 2
PFS curves of patients treated with trastuzumab plus pertuzumab in combination with chemotherapy in different treatment lines. PFS, progression-free survival.
Figure 3
Figure 3
PFS curves of trastuzumab plus pertuzumab in combination with chemotherapy in patients with and without primary resistance to trastuzumab. PFS, progression-free survival.
See this image and copyright information in PMC

References

    1. Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet 2021;397:1750-69. 10.1016/S0140-6736(20)32381-3 - DOI - PubMed
    1. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-68. 10.1634/theoncologist.2008-0230 - DOI - PubMed
    1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. 10.1126/science.3798106 - DOI - PubMed
    1. Cossetti RJ, Tyldesley SK, Speers CH, et al. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. J Clin Oncol 2015;33:65-73. 10.1200/JCO.2014.57.2461 - DOI - PubMed
    1. Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020;21:519-30. 10.1016/S1470-2045(19)30863-0 - DOI - PubMed